Condition
Byler Disease
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Unknown3
Clinical Trials (3)
Showing 3 of 3 trials
NCT02094222UnknownPrimary
Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease
NCT01949766UnknownPrimary
Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease
NCT01784718UnknownPrimary
Buphenyl Therapy for Byler's Disease
Showing all 3 trials